CalciMedica announced its third quarter 2026 financial results, highlighting $13.8 million in cash to fund operations into late 2027. The company is progressing clinical trials for its pulmonary hypertension drug Auxora, with Phase 1b trial data and an IND submission for oral candidate CM5480 expected by mid-2027. It also received FDA alignment on a Phase 2b trial design for Auxora in acute pancreatitis, a disease with no approved treatments. A recent 1-for-5 reverse stock split improved Nasdaq compliance, and the company reported a reduced net loss compared to the prior year period.
CalciMedica's third quarter 2026 financial results are reported here with Pluang's Health sector market data as context. As of Nov 10, 2026 17:51 WIB, out of 150 priced Health-sector US stocks tradable on Pluang, 76 rose and 58 fell. Notable movers include CGC at USD 0.65 with a 4.37% increase and a typical hold time of 40 days, ABCL at USD 12.86 up 2.88%, and FLNA at USD 0.50 rising 2.38%.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
